Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPEPLD | Q6IQ20 | 19/20 | 0.61 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3794527 | 0.80 | PRMT5 (0.61) | — | |
| SCHEMBL3801840 | 0.78 | PRMT5 (0.61) | — | |
| SCHEMBL3802513 | 0.76 | KMO (0.53) | — | |
| SCHEMBL3797917 | 0.76 | RIPK2 (0.46) | — | |
| SCHEMBL3798283 | 0.71 | PRMT5 (0.61) | — | |
| SCHEMBL7786671 | 0.71 | USP30 (0.58) | — | |
| SCHEMBL3796001 | 0.69 | HPGDS (0.59) | — | |
| SCHEMBL3797249 | 0.69 | HPGDS (0.59) | — | |
| SCHEMBL3802114 | 0.69 | USP30 (0.55) | — | |
| SCHEMBL1271891 | 0.69 | KMO (0.61) | NAPEPLD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | claimed |
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
| EP-1979325-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007080382-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034454-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY | TYMP, TYMS, PIK3CA | NAPEPLD 2791/4885PIK3CB 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.